Searching for the Next Dendreon, Biovest's Emerging Cancer Vaccine



Image via Wikipedia

Non-Hodgkins Lymphoma Cell

I am always on the hunt for the next Dendreon.  Previously, I have mentioned Arqule in my article,  Is Arqule the next Dendreon?  Now possibly the future Cancer Vaccine maker, Biovest (BVTI).  Here is a news article that discusses the next possible cancer vaccine to follow Dendreon's Provenge.  Biovest is in clinical trials for Non-Hodgkins Lymphoma with BiovaxID.  Yahoo Finance  BVTI

Biovest currently is emerging from bankruptcy, so this could be a very risky trade. Read more in this Florida newspaper article titled, Accentia, Biovest prepares to leave bankruptcy.  So it will remain on my radar until things get a little better financially.

What Comes After Dendreon’s Provenge?

Patricia F. Dimond, Ph.D.
Analysis & insight: Oct 18, 2010 
 

KEYWORDS:  Cancer, Geron, Lymphoma,  Vaccines , Dendreon, Biovest, Immunotherapies, Provenge, Ovarian Cancer, AML, BiovaxID, GRNVAC1, Prima Biomed, CVac

 

New Anti-Clotting Drugs May Have Edge Over Top-Selling Plavix

Image via Wikipedia Health Care, Bristol-Myers Squibb, Sanofi Aventis, Eli Lilly, Astrazeneca

Several recent studies of drugs used to treat and prevent strokes appear to favor AstraZeneca's (AZN) Brilinta and Eli-Lilly's (LLY) Effient over Plavix. Plavix, co-marketed by Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY), is the second best-selling drug in the world.